Novel Syntheses of Tetrahydrobenzodiazepines and Dihydropyrazines via Isocyanide-Based Multicomponent Reactions of Diamines

Ahmad Shaabani,*^{,†} Ali Maleki,[†] Fatemeh Hajishaabanha,[†] Hamid Mofakham,[†] Mozhdeh Seyyedhamzeh,[†] Mojtaba Mahyari,[†] and Seik Weng Ng[‡]

Department of Chemistry, Shahid Beheshti University, 19396-4716, Tehran, Iran, and Department of Chemistry, University of Malaya, 50603, Kuala Lumpur, Malaysia

Received August 15, 2009

In this work, two novel isocyanide-based multicomponent reactions of 1,2-diamine compounds with diketene have been developed as efficient strategies for the synthesis of 2,3,4,5-tetrahydro-1*H*-benzo[*b*][1,4]diazepine-2-carboxamides with regiochemical control and 1,6-dihydropyrazine-2,3-dicarbonitriles in good to excellent yields at ambient temperature.

Introduction

Benzodiazepines¹ and pyrazines² are widely used in medicinal chemistry. Benzodiazepines as one of the most widely prescribed class of psychotropics,³ which have remarkable central nervous system depressant activity,⁴ with various biological interest⁵ have been extended to various diseases such as cancer,⁶ viral infection (HIV),⁷ and cardio-vascular disorders.⁸ Pyrazines, which are biosynthesized from amino acids, are common units in a wide variety of marine natural products showing cytostatic and antitumor properties,⁹ and pyrazinamides¹⁰ as well as pyrazinesters¹¹ have been successfully evaluated in vitro and in vivo for antituberculosis activity. 2,3-Dicyanopyrazines are very useful starting materials for subsequent heterocyclization such as azaphthalocyanines,¹² tetrazoles,¹³ and nucleophilic substitutions of a nitrile and polycyclic quinoxalines.¹⁴

Diazepam I is the first marketed drug of benzodiazepine derivatives possessing anxiolytic, anticonvulsant, hypnotic, sedative, skeletal muscle relaxant, and amnestic properties.¹⁵ The benzodiazepine core is indeed a "privileged scaffold"¹⁶ found in compounds active against a variety of target types including therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis II^{17} and peptide hormones III.¹⁸ CB1 Cannabinoid receptor antagonists IV^{19} are another example of six-membered ring analogs from pyrazine heterocycles (Figure 1).

Recently, benzodiazepines have been the object of intense investigations in organic synthesis and medicinal chemistry and several approaches have been reported for the synthesis of this heterocyclic compounds.²⁰ However, the development of new synthetic routes for the preparation of pyrazine and benzodiazepine derivatives acquired relevance in recent years.

In view of our current studies on isocyanide-based multicomponent reactions (IMCRs) of diamines²¹ and

diketene,²² herein, we wish to report two hitherto unknown IMCRs which afford 2,3,4,5-tetrahydro-1*H*-benzo[*b*][1,4]-diazepine-2-carboxamides **4** with regiochemical control via a condensation reaction between an isocyanide **1**, diketene **2**, and an aromatic 1,2-diamine (AD) **3**. Alternatively, using 2,3-diaminomaleonitrile (DAMN) **5** instead of AD produces 1,6-dihydropyrazine-2,3-dicarbonitriles **6** in good to excellent yields at ambient temperature (Scheme 1).

Results and Discussion

In a pilot experiment, *o*-phenylenediamine, diketene, and cyclohexyl isocyanide were stirred in acetonitrile at room temperature. The progress of the reaction was monitored by TLC until *o*-phenylenediamine as limiting reactant of the reaction was consumed after 4 h. However, in the event, seven-membered ring compound **8a** was generated and nucleophilic attack by isocyanide did not occur. On the other hand, the predicted mechanism was not observed under the given reaction conditions, and the isolated product was 4-methyl-1*H*-benzo[*b*][1,4]diazepin-2(3*H*)-one **8a**.

It is interesting to note that compound **8a** in the presence of p-TsOH \cdot H₂O was reacted with isocyanide and produced the compound **4a** (Scheme 2).

To evaluate the use of this interesting approach, a variety of ADs carrying electron-releasing groups such as CH₃ (4d-j), electron-withdrawing groups such as COPh (4k) and halogenated diamines (4l-n), and aliphatic, alicyclic, and aromatic isocyanides were reacted under similar circumstances. The results are summarized in Table 1. The twostep reaction proceeded very efficiently under mild conditions at room temperature to produce the corresponding 2,3,4,5tetrahydro-1*H*-benzo[*b*][1,4]diazepine-2-carboxamide derivatives 4a-n in high yields. The structures of compounds 4a-n were deduced from their IR, mass, ¹H NMR, and ¹³C NMR spectral data.

The first step of this reaction was highly regioselective. It may be explained that the selectivity is due to the electronic effect of the electron-releasing groups such as CH_3 at the para position is activated exclusively, and product **8A** (not

^{*} Corresponding author. E-mail: a-shaabani@cc.sbu.ac.ir.

[†] Shahid Beheshti University.

[‡] University of Malaya.





Figure 1. Examples of medicinal benzodiazepine and pyrazine derivatives.

Scheme 1. Synthesis of 2,3,4,5-Tetrahydro-1H-benzo[b][1,4]diazepine-2-carboxamides 4 and 1,6-Dihydropyrazine-2,3-dicarbonitriles 6



Scheme 2. Synthesis of Compound 4a




Table 1. Synthesis of 2,3,4,5-Tetrahydro-1*H*-benzo[*b*][1,4]diazepine-2-carboxamides 4a-n

entry	isocyanide	diamine	product	time (h)	yield ^a (%)
1	cyclohexyl isocyanide	o-phenylenediamine	4a	5	90
2	tert-butyl isocyanide	o-phenylenediamine	4b	6	82
3	1,1,3,3-tetramethylbutyl isocyanide	o-phenylenediamine	4c	6	80
4	cyclohexyl isocyanide	4,5-dimethyl-o-phenylenediamine	4d	4	92
5	tert-butyl isocyanide	4,5-dimethyl-o-phenylenediamine	4e	4	88
6	1,1,3,3-tetramethylbutyl isocyanide	4,5-dimethyl-o-phenylenediamine	4f	5	80
7	2,6-(Me) ₂ phenyl isocyanide	4,5-dimethyl-o-phenylenediamine	4g	5	86
8	benzyl isocyanide	4,5-dimethyl-o-phenylenediamine	4h	5	85
9	cyclohexyl isocyanide	4-methyl-o-phenylenediamine	4i	5	90
10	benzyl isocyanide	4-methyl-o-phenylenediamine	4j	6	85
11	cyclohexyl isocyanide	3,4-diaminobenzophenone	4k	7	75
12	cyclohexyl isocyanide	4,5-dichloro-o-phenylenediamine	41	7	87
13	1,1,3,3-tetramethylbutyl isocyanide	4,5-dichloro-o-phenylenediamine	4m	7	80
14	benzyl isocyanide	4,5-dichloro-o-phenylenediamine	4n	7	80

^a Isolated yield.




Figure 2. Structure of intermediate products.

8A') is formed. While in the case of electron-withdrawing groups such as COPh, which deactivate the para amino group, the reaction is initiated by the meta amino group to give **8B** (not **8B**') as the favored product (Figure 2).

The structure of the product **4i** was confirmed unambiguously by single-crystal X-ray analysis (Figure 3).




Figure 3. ORTEP diagram for 4i.

In addition, three substituents in the products can be varied to yield diversity of molecules for chemical library. Representative examples of this reaction are shown in Figure 4.

The suggested mechanism for the formation of products 4a-n is illustrated in Scheme 3. It is conceivable that, the initial event is the formation of β -keto amide 7 from





Figure 4. Structure of 2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-2-carboxamides 4a-n.

Scheme 3. Possible Mechanism for the Formation of Products 4a-n



nucleophilic attack of **3** to the carbonyl (lactone) site of **2**. The product **8** was formed by intramolecular nucleophilic attack of amine to ketone. On the basis of the well-established chemistry of reaction of isocyanides with imines,²³ intermediate **10** was produced by nucleophilic attack of isocyanide **1** to activated iminium **9** followed by nucleophilic attack of an H₂O molecule on the nitrilium moiety and production of compound **11**. Finally, tautomerization of intermediate **11** produces 2,3,4,5-tetrahydro-1*H*-benzo[*b*][1,4]diazepine-2-carboxamide derivatives **4a**–**n**.

In order to investigate the scope and limitations of this reaction, we decided to extend it to 2,3-diaminomaleonitrile (DAMN) instead of aromatic 1,2-diamines (ADs). In this regard, DAMN, diketene, and cyclohexyl isocyanide in acetonitrile were stirred at room temperature. The progress of the reaction was monitored by TLC. After 20 h, the reaction was completed and 5-(cyclohexylamino)-6,6-dimethyl-1,6-dihydropyrazine-2,3-dicarbonitrile **6a** was obtained in 90% yield. To evaluate the use of this approach, a variety of aliphatic, alicyclic, and aromatic isocyanides as a third component of this reaction was condensed under similar circumstances. The results are shown in Table 2, and the structures of the products 1,6-dihydropyrazine-2,3-dicarbonitriles **6a**-**e** are demonstrated in Figure 5.

 Table 2.
 Synthesis of 1,6-Dihydropyrazine-2,3-dicarbonitrile

 Derivatives 6a-e
 6a-e

entry	isocyanide	product	time (h)	yield ^a (%)
1	cyclohexyl isocyanide	6a	20	90
2	tert-butyl isocyanide	6b	24	85
3	1,1,3,3-tetramethylbutyl isocyanide	6с	$24(15)^b$	$50(85)^{b}$
4	ethyl 2-isocyanoacetate	6d	24	85
5	benzyl isocyanide	6e	24	85

^a Isolated yield. ^b Under refluxing conditions.





Figure 5. Structure of 1,6-dihydropyrazine-2,3-dicarbonitriles 6a-e.

This reaction proceeded very cleanly under mild conditions at room temperature and no undesirable side reactions were observed. The reaction was compatible with a wide range of isocyanides. Treatment of *tert*-butyl-, 2,6-dimethylphenyl-, and benzyl isocyanides, and ethyl 2-isocyanoacetate with DAMN in the presence of diketene in acetonitrile at ambient temperature led to the formation of the corresponding 1,6dihydropyrazine-2,3-dicarbonitrile derivatives in high yields. Only, in the case of 1,1,3,3-tetramethylbutyl isocyanide after 24 h, the reaction yield was 50%. It is important to note that, when this reaction was performed under reflux conditions in CH₃CN, yield of the reaction increased to 85% after 15 h (Table 2, entry 3).

The possible mechanism for the formation of products 6a-e is shown in Scheme 4. It is very interesting that the initial event is the formation of acetoacetic acid 12 from the reaction of diketene 2 with trace water of the reaction media.²⁴ Then, the intermediate 13 was produced from the nucleophilic attack of DAMN 5 to the ketone site of 12.



Imine 14 was obtained through decarboxylation of 13.²⁴ On the basis of the well established chemistry of the reaction of isocyanides with imines,²³ intermediate 15 was produced by nucleophilic attack of isocyanide 1 to imine 14, followed by an intramolecular nucleophilic attack by the NH₂ group on the activated nitrile moiety, intermediate 16 is produced. Finally, imine-enamine tautomerization of intermediate 16 produces 1,6-dihydropyrazine-2,3-dicarbonitrile derivatives **6a–e**.

Conclusions

In summary, we have developed a novel one-pot two-step protocol for the synthesis of 2,3,4,5-tetrahydro-1*H*benzo[*b*][1,4]diazepine-2-carboxamide derivatives with regiochemical control and a novel one-pot IMCR for the synthesis of 1,6-dihydropyrazine-2,3-dicarbonitrile derivatives from condensation reactions between diketene, various isocyanides, and aromatic 1,2-diamines or 2,3-diaminomaleonitrile, respectively. We showed that diketene participates in two different ways in reactions with diamines and isocyanides. These two novel reactions can be regarded as efficient approaches for the preparation of pharmaceutically relevant tetrahydrobenzodiazepine and dihydropyrazine derivatives in good to excellent yields at ambient temperature.

Experimental Section

Typical Procedure for the Synthesis of N-Cyclohexyl-2methyl-4-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-2-carboxamide (4a). A solution of o-phenylenediamine (0.108 g, 1 mmol) and diketene (0.084 g, 1 mmol) was stirred in 3 mL of CH₃CN for 4 h at ambient temperature. After completion of the reaction, as indicated by TLC (ethyl acetate/n-hexane, 2/1), cyclohexyl isocyanide (0.109 g, 1 mmol) and p-TsOH · H₂O (0.195 g, 1 mmol) were added to the mixture. After completion of the reaction, as indicated by TLC (ethyl acetate/n-hexane, 3/1) after 1 h, the compound 4a was produced. After that, the precipitate was filtered off and washed with water, and then crystallized from acetone to give 4a as colorless crystals. mp 263–265 °C. IR (KBr) cm⁻¹: 3347, 3295, 3200, 3139, 3087, 2926, 2851, 1675, 1634, 1597, 1526, 1449, 1376. ¹H NMR (300.13 MHz, DMSO- d_6) δ : 1.00–1.70 (13H, m, 5CH₂ of cyclohexyl and CH₃), 2.39 (2H, br s, CH₂), 3.52 (1H, m, CH of cyclohexyl), 5.34 (1H, br s, NH), 6.85 (2H, br s, H–Ar), 6.95 (2H, br s, H–Ar), 7.64 (1H, br s, NH–CO), 9.55 (1H, br s, NH–CO). ¹³C NMR (75.47 MHz, DMSO- d_6) δ : 24.9, 25.0, 25.6, 26.6, 32.6, 32.8, 43.4, 48.2, 67.7, 121.9, 122.0, 122.6, 125.0, 131.3, 138.7, 170.4, 173.2. MS m/z: 302 (M⁺ + 1, 30), 175 (100), 133 (85), 55 (14), 41 (23). Anal. Calcd for C₁₇H₂₃N₃O₂: C, 67.75; H, 7.69; N, 13.94; found C, 67.65; H, 7.74; N, 13.84.

Typical Procedure for the Synthesis of 5-(Cyclohexylamino)-6,6-dimethyl-1,6-dihydropyrazine-2,3-dicarbonitrile (6a). A solution of DAMN (0.108 g, 1 mmol), diketene (0.084 g, 1 mmol), and cyclohexyl isocyanide (0.109 g, 1 mmol) in 3 mL of CH₃CN was stirred for 20 h at ambient temperature. After completion of the reaction, as indicated by TLC (ethyl acetate/n-hexane, 3/1), the precipitate was filtered off, and then crystallized from acetone to give 6a as colorless crystals. mp 252–254 °C. IR (KBr) cm⁻¹: 3343, 3081, 2931, 2852, 2217, 1579, 1539, 1451, 1391. ¹H NMR (300.13 MHz, DMSO-*d*₆) δ: 1.00–2.10 (16H, m, 5CH₂ of cyclohexyl and 2CH₃), 3.69 (1H, m, CH of cyclohexyl), 6.86 (1H, d, J = 7.6 Hz, NH), 7.12 (1H, br s, NH). ¹³C NMR (75.47 MHz, DMSO-*d*₆) δ: 24.3, 25.2, 25.7, 31.9, 49.6, 50.0, 110.2, 110.8, 114.9, 118.4, 155.8. MS m/z: 257 (M⁺, 20), 242 (25), 175 (25), 160 (100), 133 (22), 57 (45), 41 (75). Anal. calcd for C₁₄H₁₉N₅: C, 65.34; H, 7.44; N, 27.22; found C, 65.28; H, 7.33; N, 27.20.

Acknowledgment. We gratefully acknowledge financial support from the Research Council of Shahid Beheshti University.

Supporting Information Available. Experimental procedures, Mass, IR, ¹H NMR, and ¹³C NMR spectra for compounds 4a–n, 6a–e, and 8d–h, and crystallographic data for 4f and 4i (CIF). This material is available free of charge via the Internet at http://pubs.acs.org.

References and Notes

- (1) Horton, D. A.; Bourne, G. T.; Smythe, M. L. *Chem. Rev.* **2003**, *103*, 893–930.
- (2) (a) Dembitsky, V. M.; Gloriozova, T. A.; Poroikov, V. V. *Mini-Rev. Med. Chem.* 2005, *5*, 319–336. (b) Gryszkiewicz-Wojtkielewicz, A.; Jastrzebska, I.; Morzycki, J. W.; Romanowska, D. B. *Curr. Org. Chem.* 2003, *7*, 1257–1277. (c) Buron, F.; Ple, N.; Turck, A.; Queguiner, G. *J. Org. Chem.* 2005, *70*, 2616–2621. (d) Elmaaty, T. A.; Castle, L. W. *Org. Lett.* 2005, *7*, 5529–5530. (e) Bonde, C. G.; Gaikwad, N. J. *Bioorg. Med. Chem.* 2004, *12*, 2151–1254. (f) Gohlke, H.; Gundisch, D.; Schwarz, S.; Seitz, G.; Tilotta, M. C.; Wegge, T. *J. Med. Chem.* 2002, *45*, 1064–1072.
- (3) Michelini, S.; Cassano, G. B.; Frare, F.; Perugi, G. Pharmacopsychiatry 1996, 29, 127–134.
- (4) (a) Archer, G. A.; Sternbach, L. H. Chem. Rev. 1968, 68, 747–784. (b) Hamor, T. A.; MartinI. L. In Progress in Medicinal Chemistry; Ellis, G. P., West, G. B., Eds.; Elsevier Science Publishers: Amsterdam, 1983; Vol. 20. (c) Langnickel, R.; Bluth, R.; Ott, T. Pharmazie 1986, 41, 689–693. (d) Parola, A. L.; Yamamura, H. I.; Laird, H. E. Life Sci. 1993, 52, 1329–1342.
- (5) (a) Knabe, J.; Buech, H. P.; Bender, S. Arch. Pharm. 1995, 328, 59–66. (b) Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S. Drugs 1980, 20, 161–178.
- (6) Atwal, K. S.; Bergey, J. L.; Hedberg, A.; Moreland, S. J. Med. Chem. 1987, 30, 635–640.

- (7) (a) Merluzzi, V.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C.-K.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A. S.; Faanes, R.; Eckner, R. J.; Koup, R. A.; Sullivan, J. L. *Science* **1990**, *250*, 1411–1413.
 (b) Di Braccio, M.; Grossi, G.; Roma, G.; Vargiu, L.; Mura, M.; Marongiu, M. E. *Eur. J. Med. Chem.* **2001**, *36*, 935–949.
- (8) (a) Werner, W.; Baumgart, J.; Burckhardt, G.; Fleck, W. F.; Geller, K.; Gutsche, W.; Hanschmann, H.; Messerschmidt, A.; Roemer, W. *Biophys. Chem.* **1990**, *35*, 271–285. (b) Claremon, D. A.; Liverton, N.; Selnick, H. G.; Smith, G. R. Novel (*N*-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1Hbenzo[b][1,4]diazepin-3yl)-acetamides. PCT Int. Appl. WO 9640653, 1996.
- (9) (a) Betancor, C.; Freire, R.; Perez-Martin, I.; Prange, T.; Suarez, E. *Tetrahedron* 2005, *61*, 2803–2814. (b) Li, W.; Fuchs, P. L. *Org. Lett.* 2003, *5*, 2849–2852. (c) LaCour, T. G.; Guo, C.; Boyd, M. R.; Fuchs, P. L. *Org. Lett.* 2000, *2*, 33– 36.
- (10) (a) Fukuwatari, T.; Sugimoto, E.; Shibata, K. *Biosc. Biotech. Biochem.* 2002, *66*, 1435–1441. (b) Suzuki, Y.; Suzuki, A.; Tamaru, A.; Katsukawa, C.; Oda, H. *J. Clin. Microbiol.* 2002, *40*, 501–507.
- (11) (a) Cynamon, M. H.; Speirs, R. J.; Welch, J. T. Antimicrob. Agents Chemother. 1998, 42, 462–463. (b) Bergmann, K. E.; Cynamon, M. H.; Welch, J. T. J. Med. Chem. 1996, 39, 3394– 3400.
- (12) Zimcik, P.; Miletin, M.; Musil, Z.; Kopecky, K.; Slajsova, D. Dyes Pigments 2008, 77, 281–287.
- (13) Guillou, S.; Jacob, G.; Terrier, F.; Goumont, R. *Tetrahedron* 2009, 65, 8891–8895.
- (14) Ahmad, A. R.; Mehta, L. K.; Parrick, J. J. Chem. Soc., Perkin Trans. 1 1996, 2443–2449.
- (15) Mandrioli, R.; Mercolini, L.; Raggi, M. A. Curr. Drug Metab. 2008, 9, 827–44.
- (16) (a) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S. *J. Med. Chem.* **1988**, *31*, 2235–2246.
 (b) Herpin, T. F.; Van Kirk, K. G.; Salvino, J. M.; Yu, S. T.; Labaudiniere, R. F. *J. Comb. Chem.* **2000**, *5*, 513– 521.
- (17) (a) Ohtake, Y.; Fukaya, Y. E. 2,3,4,5-Tetrahydro-1*H*-1,5benzodiazepine derivative and medicinal composition. Patent 1820799A1, 2007. (b) Finch, H.; Shah, P.; Carr, R. A. E. 1,5-

Shaabani et al.

benzodiazepine derivatives having CCK and/or gastrin antagonistic activity. U.S. Patent 5,585,376, 1996.

- (18) Tranquillini, M. E.; Cassara, P. G.; Corsi, M.; Curotto, G.; Donati, D.; Finizia, G.; Pentassuglia, G.; Polinelli, S.; Tarzia, G.; Ursini, A.; Van Amsterdam, F. T. M. Arch. Pharm. **1997**, *330*, 353–357.
- (19) Barth, F. Annu. Rep. Med. Chem. 2005, 40, 103-118.
- (20) (a) Kruse, H. Drug Dev. Res. 1982, 2, 145-151. (b) Ursini, A.; Capelli, A. M.; Carr, R. A. E.; Cassara, P.; Corsi, M.; Curcuruto, O.; Curotto, G.; Cin, M. D.; Davalli, S.; Donati, D.; Feriani, A.; Finch, H.; Finizia, G.; Gaviraghi, G.; Marien, M.; Pentassuglia, G.; Polinelli, S.; Ratti, E.; Reggiani, A.; Tarzia, G.; Tedesco, G.; Tranquillini, M. E.; Trist, D. G.; Van Amsterdam, F. T. M. J. Med. Chem. 2000, 43, 3596-3613. (c) Herpin, T. F.; Van Kirk, K. G.; Salvino, J. M.; Yu, S. T.; Labaudiniere, R. F. J. Comb. Chem. 2000, 2, 513-521. (d) Cepanec, I.; Litvic, M.; Pogorelic, I. Org. Process Res. Dev. 2006, 10, 1192-1198. (e) Zhao, H. Y.; Liu, G. J. Comb. Chem. 2007, 9, 1164–1176. (f) De Silva, R. A.; Santra, S.; Andreana, P. R. Org. Lett. 2008, 10, 4541-4544. (g) Butini, S.; Gabellieri, E.; Huleatt, P. B.; Campiani, G.; Franceschini, S.; Brindisi, M.; Ros, S.; Coccone, S. S.; Fiorini, I.; Novellino, E.; Giorgi, G.; Gemma, S. J. Org. Chem. 2008, 73, 8458-8468. (h) Reid, W.; Stahlofen, P. Chem. Ber. 1957, 90, 825-828
- (21) (a) Shaabani, A.; Maleki, A.; Moghimi-Rad, J. J. Org. Chem.
 2007, 72, 6309–6311. (b) Shaabani, A.; Maleki, A.; Mofakham, H.; Khavasi, H. R. J. Comb. Chem. 2008, 10, 323–326. (c) Shaabani, A.; Maleki, A.; Mofakham, H.; Moghimi-Rad, J. J. Org. Chem. 2008, 73, 3925–3927. (d) Shaabani, A.; Maleki, A.; Mofakham, H. J. Comb. Chem. 2008, 10, 595–598. (e) Shaabani, A.; Rezayan, A. H.; Keshipour, S.; Sarvary, A.; Ng, S. W. Org. Lett. 2009, 11, 3342–3345.
- (22) (a) Shaabani, A.; Seyyedhamzeh, M.; Maleki, A.; Rezazadeh, F.; Behnam, M. J. Comb. Chem. 2009, 11, 375–377. (b) Shaabani, A.; Seyyedhamzeh, M.; Maleki, A.; Behnam, M.; Rezazadeh, F. Tetrahedron Lett. 2009, 50, 2911–2913. (c) Shaabani, A.; Seyyedhamzeh, M.; Maleki, A.; Behnam, M. Tetrahedron Lett. 2009, 50, 6355–6357.
- (23) (a) Dömling, A.; Ugi, I. Angew. Chem., Intl. Ed. 2000, 39, 3168–3210. (b) Dömling, A. Chem. Rev. 2006, 106, 17–89. (c) El Kaim, L.; Grimaud, L. Tetrahedron 2009, 65, 2153–2171. (d) Ganem, B. Acc. Chem. Res. 2009, 42, 463–472.
- (24) Clemens, R. J. Chem. Rev. 1986, 86, 241-318.

CC900125A